Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are primary 4-repeat tauopathies in which pathological tau accumulates not only in neurons, but also in glial cells.[1][2] While neuronal globose tangles and dystrophic neurites remain central lesions, glial pathology provides a major anatomical and mechanistic axis that helps explain selective network vulnerability, disease spread patterns, and clinicopathologic heterogeneity.[3][4]
The two most distinguishing glial lesions are tufted astrocytes in PSP and astrocytic plaques in CBD, with oligodendroglial coiled bodies present in both conditions.[5][6] These lesions are not passive markers. They are tightly linked to region-specific degeneration in basal ganglia, brainstem, and frontoparietal cortical circuits, and they track with clinical phenotypes such as postural instability, vertical gaze dysfunction, apraxia, asymmetric rigidity, and cognitive-behavioral syndromes.[2:1][7]
This page frames glial tau pathology as an integrated systems mechanism connecting 4R Tauopathy Molecular Mechanisms, microglia, astrocyte-neuron metabolic coupling, oligodendrocyte support failure, and white-matter disconnection.
PSP is characterized by tau-positive astrocytes with dense perisomatic and proximal process inclusions, producing the classic "tufted" appearance.[5:1][8] Lesions are prominent in motor and premotor circuits including subthalamic nucleus, globus pallidus, substantia nigra, and brainstem structures involved in oculomotor and postural control.[2:2][9]
From a mechanistic standpoint, tufted astrocytes indicate failure of astrocytic proteostasis and cytoskeletal homeostasis under sustained 4R-tau stress. Astrocytes normally buffer extracellular glutamate, lactate-shuttle neurons, and stabilize ionic and vascular microenvironments. Tau-loaded astrocytes show reduced support functions and increased inflammatory signaling, amplifying local network fragility.[10][11]
CBD shows a different astroglial morphology: astrocytic plaques, usually in cortex and subcortical white matter, with ring-like tau-positive distal processes and relative sparing of the soma.[6:1][12] This pattern aligns with corticobasal clinical phenotypes involving asymmetric cortical dysfunction (apraxia, cortical sensory loss, alien limb phenomena) and disconnection syndromes.[7:1][13]
Compared with PSP tufted astrocytes, CBD plaques suggest stronger involvement of cortical astrocyte domains and local white-matter interfaces, potentially reflecting different seeding microenvironments, cell-type vulnerabilities, or regional strain selection within the 4R-tau conformational landscape.[14][15]
Oligodendroglial coiled bodies are common in both PSP and CBD.[3:1][16] Their presence implies that myelin-support and axon-glia interactions are integral components of disease biology rather than downstream epiphenomena. Oligodendrocytes under tau burden may fail to maintain high-metabolic axonal tracts, increasing long-range network disintegration and impairing compensatory plasticity.[16:1][17]
Astrocytes can internalize extracellular tau species via endocytic and receptor-mediated routes, then route cargo through lysosomal and autophagic systems.[11:1][18] In primary 4R tauopathies, sustained seed exposure appears to exceed degradation capacity, resulting in persistent inclusions and glial morphological remodeling.[10:1][14:1]
Astrocytes with tau inclusions show altered expression of inflammatory and extracellular matrix genes, and may transition toward states less capable of sustaining synaptic homeostasis.[19][20] The key problem is not merely "astrocyte activation" but a shift from supportive to maladaptive glial states that reduces system resilience.
Oligodendrocytes maintain conduction fidelity and provide metabolic support to long axons. Tau-bearing coiled bodies likely signal altered cytoskeletal transport and impaired glia-axon coupling.[16:2][21] In corticobasal and PSP pathways, this can worsen conduction delay, synchrony breakdown, and eventual tract-level disconnection, consistent with gait/postural decline and frontal-executive impairment.[9:1][17:1]
In both PSP and CBD, activated microglia are enriched around tau lesions and likely participate in both clearance attempts and inflammatory amplification.[22][23] Cytokines, complement signaling, and reactive oxygen stress can increase tau phosphorylation and reduce clearance efficiency, creating a feed-forward loop.[24][25]
PSP pathology strongly targets subcortical and brainstem motor-control nodes. Glial tau in these regions may destabilize high-throughput motor integration networks with limited redundancy, accelerating falls, axial rigidity, dysarthria, and vertical gaze dysfunction.[2:3][9:2][26]
CBD more often emphasizes perirolandic, premotor, and parietal cortical circuits, where astrocytic plaques and white-matter changes support a model of cortico-subcortical disconnection.[7:2][13:1] Asymmetry in lesion burden and network failure is consistent with the frequent asymmetric clinical onset.[13:2]
PSP and CBD likely share core 4R-tau molecular susceptibility but diverge in glial lesion geography and circuit context.[1:1][14:2] This helps explain why related diseases can show overlapping pathology classes yet distinct syndromic signatures.
Glial-centered disease models motivate biomarker strategies beyond global tau load:
For intervention trials, glial tau biology suggests three design principles:
A pragmatic mechanistic framework for PSP/CBD glial targeting includes:
This layered model predicts that monotherapy against one node may be insufficient in established disease. Mechanistically staged combination regimens may better address the self-reinforcing glia-neuron pathology loop.
This mechanism connects directly with:
Kovacs GG. 'Invited review: Neuropathology of tauopathies: principles and practice'. Neuropathology and Applied Neurobiology. 2021. ↩︎ ↩︎ ↩︎
Höglinger GU, Respondek G, Stamelou M, et al. 'Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria'. Movement Disorders. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology. 2010. ↩︎ ↩︎ ↩︎
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013. ↩︎
Williams DR, Lees AJ. 'Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges'. The Lancet Neurology. 2009. ↩︎ ↩︎ ↩︎ ↩︎
Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. Journal of Neuropathology and Experimental Neurology. 2002. ↩︎ ↩︎ ↩︎
Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Komori T. Tau-positive glial inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology. 2008. ↩︎
Whitwell JL, Avula R, Master A, et al. Disrupted thalamocortical connectivity in PSP and CBD. Neurology. 2011. ↩︎ ↩︎ ↩︎
Kahlson MA, Colodner KJ. 'Glial tau pathology in tauopathies: functional consequences'. Acta Neuropathologica Communications. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Perea JR, López E, Díez-Ballesteros JC, et al. Extracellular monomeric tau is internalized by astrocytes. Frontiers in Neuroscience. 2019. ↩︎ ↩︎ ↩︎
Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome. Acta Neuropathologica. 2011. ↩︎
Burrell JR, Hodges JR, Rowe JB. 'Corticobasal syndrome: a practical guide'. Practical Neurology. 2014. ↩︎ ↩︎ ↩︎
Vaquer-Alicea J, Diamond MI. Propagation of protein aggregation in neurodegenerative diseases. Annual Review of Biochemistry. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021. ↩︎ ↩︎
Ahmed Z, Bigio EH, Budka H, et al. Globular glial tauopathies and glial tau pathology overview. Acta Neuropathologica. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Upadhyay N, Suppa A, Piattella MC, et al. Diffusion MRI signatures in PSP and CBD. Parkinsonism & Related Disorders. 2017. ↩︎ ↩︎
Martinez-Vicente M. Neuronal and glial autophagy in neurodegenerative diseases. FEBS Letters. 2015. ↩︎
Grubman A, Chew G, Ouyang JF, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease reveals cell-type-specific gene expression regulation. Nature Neuroscience. 2019. ↩︎ ↩︎
Habib N, McCabe C, Medina S, et al. Disease-associated astrocytes in Alzheimer's disease and aging. Nature Neuroscience. 2020. ↩︎
Philips T, Rothstein JD. Oligodendroglia and metabolic support in neurodegeneration. Trends in Neurosciences. 2017. ↩︎ ↩︎
Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of α-synuclein and tau interaction and neuroinflammation. Cell and Tissue Research. 2020. ↩︎ ↩︎
Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in PSP. Journal of Neuropathology and Experimental Neurology. 2001. ↩︎
Ising C, Venegas C, Zhang S, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019. ↩︎ ↩︎
Laurent C, Buée L, Blum D. 'Tau and neuroinflammation: what impact for Alzheimer''s disease and tauopathies?'. Biomedicine & Pharmacotherapy. 2018. ↩︎
Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy. Movement Disorders. 2017. ↩︎
Brendel M, Schönecker S, Höglinger G, et al. Advances in tau PET and multimodal imaging in PSP/CBD. Movement Disorders. 2023. ↩︎
Whitwell JL, Lowe VJ, Tosakulwong N, et al. Imaging correlates of pathology and clinical progression in corticobasal syndrome. Neurology. 2017. ↩︎ ↩︎
Ashton NJ, Janelidze S, Al Khleifat A, et al. Plasma biomarkers in atypical parkinsonian disorders. Nature Medicine. 2022. ↩︎
Barthelemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine. 2020. ↩︎
Boxer AL, Lang AE, Grossman M, et al. 'Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial'. The Lancet Neurology. 2014. ↩︎
Tsai RM, Boxer AL. Treatment of frontotemporal dementia and related tauopathies. Current Treatment Options in Neurology. 2020. ↩︎
Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nature Reviews Neurology. 2018. ↩︎